Kancera Investor Relations Material
Latest events
Study Update
Kancera
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kancera
Access all reports
Kancera AB is a Swedish biotechnology company focusing on developing pharmaceuticals for the treatment of severe diseases, particularly cancer and inflammatory conditions. The company's efforts are primarily directed towards creating small molecule drug candidates that target disease-promoting immune and cancer cells, specifically utilizing the fractalkine axis. Kancera's work is divided into two main areas: Pharmaceutical Development and Industrial Research and Development (R&D). Solna, Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
KAN
Country
🇸🇪 Sweden